Your browser doesn't support javascript.
loading
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.
Matsumoto, Julia; Kiesel, Brian F; Parise, Robert A; Guo, Jianxia; Taylor, Sarah; Huang, Marilyn; Eiseman, Julie L; Ivy, S Percy; Kunos, Charles; Chu, Edward; Beumer, Jan H.
Afiliación
  • Matsumoto J; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States; School of Pharmaceutical Sciences, Sao Paulo State University, Araraquara, SP, Brazil.
  • Kiesel BF; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States.
  • Parise RA; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States.
  • Guo J; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States.
  • Taylor S; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Pittsburgh-Magee Women's Hospital, Pittsburgh, PA, United States.
  • Huang M; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Pittsburgh-Magee Women's Hospital, Pittsburgh, PA, United States.
  • Eiseman JL; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
  • Ivy SP; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.
  • Kunos C; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.
  • Chu E; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
  • Beumer JH; Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; Department of Pharmaceutical Sciences, School of Pharmacy, Unive
J Pharm Biomed Anal ; 146: 154-160, 2017 Nov 30.
Article en En | MEDLINE | ID: mdl-28881312
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Plasma / Piridinas / Ribonucleótido Reductasas / Tiosemicarbazonas / Inhibidores Enzimáticos Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: J Pharm Biomed Anal Año: 2017 Tipo del documento: Article País de afiliación: Brasil
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Plasma / Piridinas / Ribonucleótido Reductasas / Tiosemicarbazonas / Inhibidores Enzimáticos Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: J Pharm Biomed Anal Año: 2017 Tipo del documento: Article País de afiliación: Brasil